Valeant previously offered tiered volume rebates of up to 30% for hospitals which use the drugs the most.
Advertisement
But Senator McCaskill quickly jumped on this claim, saying she had surveyed large and small hospitals in Missouri and found zero hospitals which had received the discounts.
And The New York Times reported on Tuesday that numerous major drug companies have been quietly raising prices even more since then.
“There is not going to be any bankruptcy of Valeant”, he said.
Numerous allegations against the likes of Turing and Valeant stress the fact that these companies do not actually conduct research and develop medical products, but instead acquire drugs, raise the prices and profit off the price increases.
Since joining Valeant as CEO in 2008, Mr. Pearson has followed a strategy of ignoring R&D in favor of acquiring undervalued drug companies, stripping them to their core, then relaunching their key assets to market with steep price increases attached.
After that acquisition, Valeant increased the price of Isuprel by about 720 percent and Nitropress by 310 percent.
The ailment is a rare genetic disorder that if left untreated causes a crippling and sometimes fatal buildup of copper in those struck by the illness.
Some of the most recent price increases also may be happening because drugmakers are hoping to profit while they can, before congressional or other actions prevent them from doing so, said Geoffrey Porges, the author of the Leerink analysis. Valeant got a waiver from bank lenders, hired a new chief executive, and has been preparing its long-overdue annual financial statement, which he said would be filed publicly by Friday.
Pearson highlighted the company’s 20-year program with Walgreens Boots Alliance that will give up to 95 per cent discounts on certain branded medications that have generic alternatives, and pointed to the more than $1 billion Valeant expects to spend on patient assistance in 2016.
The patient, Berna Heyman, testified that Valeant refused to help her when she called to complain about the prices.
“You’re not in this business to lose money”, she said.
Aberrations or business as usual? Ackman also sits on Valeant’s board.
Ackman said he wished he had done better due diligence.
The testimony, under sharp questioning, highlighted Valeant’s stark fall from Wall Street darling to Washington punching bag, and showed how much it has at stake. The Senate has been investigating Valeant for its pricing practices since December. The estimate is based on Valeant’s closing share price Wednesday.
“Not in the United States”, Pearson replied.
“Valeant’s monopoly model operates at the expense of real people”, Committee Chairman Susan Collins, Maine Republican, said.
The share price of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) declined -83.00 percent for the year.
During the most recent trading day, the stock’s price shifted up +38.19 percent from its 52-week-low while -86.76 percent lower from its 52-week high.
The blistering criticisms from Senate Republicans and Democrats came as Valeant’s outgoing CEO expressed regrets for the most egregious price increases and a billionaire hedge fund investor defended the company’s business model. Ackman indicated Papa would likely start next week and appeared ready to turn the page on Pearson’s tenure as CEO, despite the close relationship that once existed between the two.
In contrast, Papa’s full-year salary at Perrigo was $11.5 million in total, according to The Wall Street Journal. Adding in bonuses, options, and restricted stock bring Papa’s pay to about $67.4 million, according to Bloomberg. Those delays put Valeant in danger of defaulting on agreements with its creditors and bondholders.
Advertisement
On Wednesday, Mike Pearson, soon to be the fomer CEO of Canadian pharmaceutical company Valeant, will testifiy before Senate.
